New Gene Signature Predicts Myeloid Cancer Outcomes and Reveals mTOR as Treatment Target

Myeloid blood cancers, including acute myeloid leukemia (AML), remain challenging to treat with highly variable patient outcomes. This comprehensive study addresses a critical gap in personalized cancer medicine by developing a novel approach to predict patient survival and identify targeted treatment strategies.

Researchers analyzed genetic data from large population studies and patient cohorts to understand the relationship between myeloproliferative neoplasms (MPNs) and AML. They discovered that genetic predisposition to MPNs significantly increases AML risk, establishing MPNs as precursor conditions. Through advanced proteogenomic analysis, they identified 55 proteins associated with MPN risk and narrowed these to a 4-gene signature (CDCP1, CRISP3, DCXR, and MPO) that powerfully predicts AML patient survival.

The signature successfully stratified patients into high-risk and low-risk groups across multiple independent cohorts. High-risk patients showed median survival of 11.9 months versus 21.9 months for low-risk patients. Importantly, the research revealed that high-risk patients have increased sensitivity to PI3K/mTOR pathway inhibitors, suggesting a precision medicine approach.

Laboratory experiments validated these findings, showing that mTOR inhibition effectively suppressed cancer cell growth in both cell culture and animal models. The genes in the signature were particularly enriched in myeloid progenitor cells and cancer blasts, explaining their biological relevance.

This work represents a significant advance in blood cancer precision medicine, offering both improved prognostic tools and rational therapeutic targets. The identification of mTOR pathway vulnerability in high-risk patients could lead to more effective, personalized treatment strategies for these challenging cancers.